fashion -WSS

fashion

author：knowledge 2025-10-03 00:03:44 - browse：7863

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Complete sequence of Y chromosome published for first time

WSS

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Congress may force more Covid

Flagship Pioneering startup Sonata Therapeutics lays off 21

Researchers tackle phage therapy hurdles for wider adoption

Diversity in medical illustrations gets boost from Chidiebere Ibe

CDC advisory panel says seniors 'may' get RSV vaccine

Wikipedia

fashion

entertainment

Cancer drug shortages should be causing more outrage

Obamacare plans could cover weight loss drugs

Trump demands the U.S. pay no more for drugs than other countries … again

Hospitals are piloting generative AI tools as regulators play catch

Guidelines to prevent youth baseball injuries need more muscle

Medicare explains how it will choose drugs for negotiation

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Cancer drug shortages should be causing more outrage

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

explore

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

NYU Langone launches private ChatGPT for its health care data

Why more medical students aren't specializing in primary care

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Study finds new variant for Parkinson’s in African populations

Flagship Pioneering startup Sonata Therapeutics lays off 21

focus

knowledge

entertainment

hotspot